Trial Profile
Effect of switching efavirenz to rilpivirine in treatment of HIV- infected patients with dyslipidemia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Efavirenz
- Indications Dyslipidaemias; HIV infections
- Focus Therapeutic Use
- 16 Sep 2016 New trial record